Status:

RECRUITING

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Solid Tumours

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Eligibility Criteria

Inclusion

  • Participants must have an ECOG performance status of 0 to 1.
  • Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator).
  • Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic solid tumors, including NSCLC, HNSCC, TNBC, and HR+/HER2- breast cancer.

Exclusion

  • Participants must not have untreated CNS metastases. Participants are eligible if CNS metastases have been treated and do not require immediate treatment or have been treated and have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment).
  • Participants must not have concurrent malignancy (present during Screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment.
  • Participants must not have history of serious recurrent infections.
  • Participants must not have impaired cardiac function or history of severe heart disease.
  • Other protocol-defined inclusion/exclusion criteria apply.

Key Trial Info

Start Date :

October 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2028

Estimated Enrollment :

315 Patients enrolled

Trial Details

Trial ID

NCT07160725

Start Date

October 15 2025

End Date

August 1 2028

Last Update

February 17 2026

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Local Institution - 0033

Irvine, California, United States, 92612

2

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

3

Local Institution - 0021

Orange, California, United States, 92868

4

Local Institution - 0008

Pittsburgh, Pennsylvania, United States, 15232